Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Part of paid clinical trials in Beverly Hills, California.
- Sponsor
- City of Hope Medical Center
- Study ID
- NCT00720876
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- rituximab — BIOLOGICALRituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
- vorinostat — DRUG200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
Study Details
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving vorinostat together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects of giving vorinostat together with rituximab and to see how well it works in treating patients with indolent non-Hodgkin lymphoma.
Key Dates
- Start date
- Jul 23, 2008
- Status verified
- Jul 2018
- Primary completion
- Jun 8, 2017
- Completion
- Jun 8, 2017
Study Design
- Enrollment
- 30 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Vorinostat and RituximabVorinostat by mouth two times (2X) per day for two weeks followed by one week of rest. Rituximab intravenously once every three weeks .
Primary Outcome Measure
Overall Response Rate (Complete and Partial Response) [ Time Frame: After every 3 cycles, up to 1 year after the start of treatment ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Tower Cancer Research Foundation | Beverly Hills | California | 90211 | - |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010-3000 | - |
| City of Hope Medical Group | Pasadena | California | 91105 | - |
Find similar trials in Beverly Hills, CA
Related Studies
- Bone Marrow Grafting for Leukemia and LymphomaEnrolling By Invitation · Stanford University · Stanford, California
- Pediatric PET/MR Image RegistryRecruiting · Stanford University · Palo Alto, California
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsPHASE1/PHASE2 · Recruiting · Turning Point Therapeutics, Inc. · Los Angeles, California
- Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S TrialPHASE3 · Recruiting · University of Rochester · Tuscaloosa, Alabama